Campesterol

Campesterol: A Comprehensive Reference Article

1. Identity and Chemical Characterization

Chemical Names and Classification

Campesterol is a member of phytosterols, a 3β-sterol, a 3β-hydroxy-Δ(5)-steroid, and a C28-steroid. Its systematic IUPAC name is (3β,24R)-ergost-5-en-3-ol, and it is also known by the synonyms (24R)-ergost-5-en-3β-ol and (24R)-24-methylcholest-5-en-3β-ol. Additional recorded synonyms include (24R)-5-ergosten-3β-ol and ergost-5-en-3-ol, (3β,24R)-. Its CAS Registry Number is 474-62-4, and its PubChem CID is 173183. The molecular formula is C₂₈H₄₈O, reflecting a molecular weight of approximately 400.68 g/mol.

Campesterol possesses a methyl group at the C-24 position of the side chain in the cholesterol structure. Like other major phytosterols, it has a hydroxyl group in the β-position at C3 and a double bond between C5–C6 (Δ5). The hydroxyl group at C3 in free phytosterols can be esterified by a fatty acid to form steryl esters, or linked to a carbohydrate to form steryl glycosides.

Campesterol is a phytosterol whose chemical structure is similar to that of cholesterol, and is one of the ingredients for E number E499. It is a plant sterol, which is an analog of cholesterol and a brassinosteroid (BR) precursor. The enzyme diminute/dwarf1 mediates the synthesis of campesterol from 24-methylenecholesterol in plants.

Nomenclature and Etymology

It is so named because it was first isolated from the rapeseed (Brassica campestris). Although campesterol wasn't identified until the mid-20th century — first isolated in 1922 from rapeseed oil — humans have consumed it unknowingly for millennia via grains, seeds, and oils.

2. Natural Sources and Distribution

Botanical and Dietary Sources

Campesterol is a natural phytosterol found in plant cell membranes. Many vegetables, fruits, nuts, and seeds contain campesterol, but in low concentrations. Banana, pomegranate, pepper, coffee, grapefruit, cucumber, onion, oat, potato, and lemon grass (citronella) are few examples of common sources containing campesterol at roughly 1–7 mg/100 g of the edible portion. In contrast, canola and corn oils contain as much as 16–100 mg/100 g. Levels are variable and are influenced by geography and growing environment.

The phytosterols found in the highest amounts in plant-based foods, and thus in the human diet, are β-sitosterol, campesterol, and stigmasterol. Food sources with the highest plant sterol content are vegetable oils, mainly corn oil, and sesame seeds.

The most commonly occurring phytosterols in the human diet are β-sitosterol, campesterol, and stigmasterol, which account for about 65%, 30%, and 3% of diet contents, respectively. The most abundant plant sterols include sitosterol, campesterol, and stigmasterol, with typical daily intakes ranging from 150 to 400 mg day⁻¹.

The main phytosterols in palm oil are sitosterol at 350–410 μg/g oil, campesterol at 140–180 μg/g oil, stigmasterol at 70–100 μg/g oil, and avenasterol at 0–30 μg/g oil. Across various plant oil samples, the major phytosterols in decreasing relative abundance were β-sitosterol (range 28–55% of total sterol content), Δ5-avenasterol (3–24%), campesterol (2–33%), Δ5-stigmasterol (0.7–18%), Δ7-stigmasterol (1–18%), and Δ7-avenasterol (0.1–5%).

Role in the Plant Kingdom

Phytosterols are essential for membrane structure and functioning of the plant cells. The phytohormone brassinosteroids (about 60 polyhydroxylated sterol derivatives) are biosynthesized from sterol precursors and regulate plant developmental processes and stress responses. Campesterol is a direct precursor in this biosynthetic pathway. A number of new genetic strains are currently being engineered with the goal of producing varieties high in campesterol and other plant sterols.

3. Traditional and Historical Use

Campesterol as an isolated compound was not identified or used in traditional medicine systems; it is a product of modern phytochemical science. Humans have consumed campesterol unknowingly for millennia via grains, seeds, and oils. Phytosterols have a long history of safe use, dating back to Cytellin, the pharmaceutical preparation of phytosterols marketed in the US from 1954 to 1982. Phytosterol esters have generally recognized as safe (GRAS) status in the US.

In Ayurveda's classical texts (Charaka Samhita, Sushruta Samhita), campesterol itself isn't named — there was no explicit reference to phytostanols or campesterol as an identified compound. Traditional cuisines historically rich in phytosterol-containing foods (whole grains, seeds, legumes, nuts, and vegetable oils) in the Mediterranean, South Asia, and East Asia would have provided dietary campesterol, though not as a deliberately isolated or targeted substance. The scientific recognition and commercial isolation of campesterol as a distinct ingredient came only with 20th-century analytical chemistry.

Over forty years ago, Eli Lilly marketed a sterol preparation from tall oil and later from soybean oil called Cytellin™, which was found to lower serum cholesterol by about 9% according to one report. This product, which contained campesterol as a component alongside other phytosterols, represents the earliest modern pharmacological use of plant sterols for cholesterol management. Phytosterol-containing functional foods were subject to post-launch monitoring after being introduced to the EU market in 2000, and no unpredicted side effects were reported.

4. Key Constituents, Chemical Forms, and Commercial Preparations

Chemical Forms

Campesterol exists in dietary and supplementary contexts in two primary forms: as a free sterol and as a sterol ester. It is difficult to incorporate free sterols into edible fats and/or oils because of their insolubility, whereas sterols esterified to fatty acids are more fat-soluble. In the intestine, most sterol esters are hydrolyzed to free sterols as part of the normal digestive process. Documented campesterol ester forms include campesterol myristearate ester, campesterol stearate ester, campesterol oleate ester, campesterol laurate ester, campesterol linoleate ester, and campesterol ricinoleate ester, among others.

Plant stanols are hydrogenation products of the respective plant sterols — for example, campestanol is derived from campesterol and sitostanol from sitosterol — and are found in nature at very low levels.

Commercial Preparations

Campesterol is not commonly sold as a standalone supplement; it is instead a significant component of mixed phytosterol preparations. A typical phytosterol composition is composed of plant sterols and stanols having 14.5% campesterol, 2.4% campostanol, 50.9% beta-sitosterol, and 18.9% sitostanol. Commercial preparations are available in multiple forms, including:

• Phytosterol-enriched margarines and spreads — enrichment of foods such as margarines with plant sterols and stanols is one of the recent developments in functional foods to enhance the cholesterol-lowering ability of traditional food products.
• Phytosterol ester emulsions designed for enhanced bioavailability in dietary supplement formats.
• Phytosterol powder preparations incorporated into capsules, tablets, and fortified foods.
• Fortified dairy products — in European Union countries, products enriched in plant sterols are mainly milk and yogurt, margarine, and spreadable fats.

Extraction Methods

Several extraction methods exist, including docking, chromatographic, gas chromatography-mass spectrometry, subcritical fluid extraction, cold-pressed, Soxhlet, mechanical shaking, silica solid-phase, and microwave-assisted extraction; however, the silica solid-phase extraction method is a highly efficient approach for isolating campesterol from plant cells. Phytosterols isolated mainly from vegetable oils and their commercially produced esters can be ingredients of fortified foods and supplements as a non-pharmacological therapy of hypercholesterolemia.

5. Mechanisms of Action

Inhibition of Intestinal Cholesterol Absorption

The most thoroughly investigated mechanism of campesterol, in the context of the broader phytosterol class, is competitive inhibition of intestinal cholesterol absorption. Though an analogue of cholesterol, campesterol is poorly absorbed in humans and competitively inhibits the absorption of cholesterol. Phytosterols and phytostanols are thought to interfere with intestinal cholesterol absorption; i.e., they are competitive inhibitors of cholesterol uptake. The molecular basis of the inhibition is not fully resolved, but suggested mechanisms include displacing cholesterol from mixed micelles, increased expression of genes encoding sterol transporter proteins (NPC1L1, ABCG5, and ABCG8) that promote cholesterol efflux from enterocytes into the intestinal lumen, decreased cholesterol reesterification rate in enterocytes, and increased cholesterol removal from the body via transintestinal cholesterol efflux.

In basic research, campesterol competes with cholesterol, thus reducing the absorption of cholesterol in the human intestine. Plant sterols may also act directly on intestinal cells and affect transporter proteins. In addition, an effect on the synthesis of cholesterol-transporting proteins has been proposed.

Transporter-Mediated Efflux: ABCG5/ABCG8 and NPC1L1

The absorption process of dietary cholesterol and plant sterols is mediated by the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine. The NPC1L1 transporter primarily absorbs dietary cholesterol, with plant sterols and stanols being absorbed to a lesser extent. The efflux transporters, ABCG5 and ABCG8, have been identified as the main proteins responsible for the active transport of plant sterols back to the intestinal lumen.

Average cholesterol absorption efficiency in humans is 56%, whereas phytosterols are not absorbed to a great extent, with absorption efficiency of campesterol being only 1.9%. Campesterol is a common dietary phytosterol and has the highest intestinal absorption efficiency among individual phytosterols.

Due to low absorption and increased biliary excretion, the concentration of plant sterols/stanols in the systemic circulation is very low (0.3–1 and 0.002–0.012 mg/dL, respectively). These levels are 500 and 10,000 times, respectively, lower than those of circulating cholesterol.

Role as a Biomarker of Cholesterol Absorption

Serum campesterol levels are used clinically as a surrogate biomarker of intestinal cholesterol absorption efficiency. Measurements of serum surrogate markers of cholesterol absorption (plant sterols: sitosterol, campesterol) and synthesis (cholesterol precursor: lathosterol) are carried out by gas chromatography/mass spectrometry (GC/MS). Based on simple ordinary least squares regression analysis, the best biomarker for dietary phytosterol intake was the ratio of plasma campesterol to the endogenous cholesterol metabolite 5-α-cholestanol (R² = 0.785, P < 0.0001). Plasma campesterol and 5-α-cholestanol levels varied greatly among subjects at the same dietary phytosterol intake level, but were positively correlated at each level in both studies (r > 0.600; P < 0.01).

Anti-Inflammatory Pathways

When inflammation is present in a pathogenic state, campesterol effectively decreases COX-2 expression. qPCR analysis has shown that campesterol reduces pro-inflammatory cytokines TNF-α, NF-κB, IL-6, COX II, and IL-1 levels while enhancing anti-inflammatory cytokine IL-4 levels. These findings are derived primarily from in vitro and in vivo (animal) experiments rather than controlled human clinical trials.

Anticancer Mechanisms (Preclinical)

Phytosterols — including campesterol — appear to act through multiple mechanisms of action, including inhibition of carcinogen production, cancer-cell growth, angiogenesis, invasion and metastasis, and through the promotion of apoptosis of cancerous cells. Phytosterol consumption may also increase the activity of antioxidant enzymes and thereby reduce oxidative stress.

A previous study indicated that campesterol from Chrysanthemum coronarium L. has antiangiogenic activities. It was surmised that an antiangiogenic effect may be involved in the anticancer action of this phytosterol.

Steroidogenic Precursor Role

Campesterol can serve as a precursor to a wide range of steroid hormones. This is because it has structural similarity to cholesterol. Anabolic steroids like testosterone and boldenone are among the compounds that can be biosynthesized from either cholesterol or phytosterols like campesterol through a process called steroidogenesis.

6. Scientific Evidence by Area of Use

6.1 Cardiovascular Health: LDL Cholesterol Reduction

The strongest and most replicated body of evidence concerning campesterol — as a component of mixed phytosterol preparations — relates to LDL cholesterol reduction. Clinical studies consistently indicate that the intake of phytosterols (2 g/day) is associated with a significant reduction (8–10%) in levels of LDL-cholesterol. Several guidelines recommend the intake of 2 g/day of plant sterols and/or stanols in order to reduce LDL-cholesterol levels.

The European Food Safety Authority (EFSA) concluded that blood cholesterol can be reduced on average by 7 to 10.5% if a person consumes 1.5 to 2.4 grams of plant sterols and stanols per day, an effect usually established within 2–3 weeks. Longer-term studies extending up to 85 weeks showed that the cholesterol-lowering effect could be sustained.

A meta-analysis of randomized controlled trials quantified this effect: plant sterol-containing products decreased LDL levels by 0.31 mmol/L (95% CI, −0.35 to −0.27, P < 0.0001) compared with placebo. A separate RCT using a phytosterol emulsion formulation found that phytosterol supplementation significantly lowered LDLc concentrations by 10.2% (16.17 mg/dL or 0.419 mmol/L, p = 0.008 by paired t-test, p = 0.014 by Wilcoxon signed rank testing) in 32 healthy adults receiving 1.5 g/day phytosterol equivalents over one month.

A meta-analysis of 124 randomized controlled trials in humans investigated the combined and separate LDLc-lowering effects of plant sterols and stanols when classified into different dose ranges. The LDLc-lowering effect continues to increase up to intakes of approximately 3 g/day to an average effect of 12%, and doses higher than 3 g/day appear to be well tolerated.

Studies have shown that consumption of 0.6–3.3 g of plant sterols per day reduces serum LDL-C concentrations by approximately 6–12%, and this effect is dose-dependent.

Campesterol is specifically used as a serum marker to track the cholesterol-absorption-lowering response: the ratio of serum lathosterol to campesterol predicts the reduction of total cholesterol and LDL cholesterol during administration of sitostanol-supplemented margarine in patients with mild hypercholesterolemia.

Evidence strength: The LDL-lowering effect of phytosterols as a class, including campesterol-containing preparations, is supported by multiple large meta-analyses of RCTs and is considered robust for the surrogate endpoint of LDL cholesterol. However, there is an important caveat regarding hard cardiovascular outcomes (see Safety section).

6.2 Cardiovascular Risk: Hard Outcomes and Unresolved Questions

Despite well-established surrogate (LDL) effects, the translation to reduced cardiovascular events remains unproven. Although phytosterols decrease LDL-cholesterol levels, there is no evidence that they reduce the risk of cardiovascular diseases; on the contrary, some studies suggest an increased risk of atherosclerosis with increasing serum levels of phytosterols.

A large meta-analysis including 17 studies (cohorts, parallel- or cross-over trials, and cross-sectional/case–control/nested case–control studies) with 11,182 individuals demonstrated no significant association of circulating campesterol (relative risk, RR: 1.02, 95% CI: 0.94–1.09) and sitosterol (RR: 1.06, 95% CI: 0.84–1.34) with the presence of CVD, although the possibility of an accumulation of plant sterols/stanols in vascular cells due to the increase in their circulating concentrations could not be excluded.

No randomized controlled trials (RCTs) have been conducted so far which assess a potential effect of phytosterol supplementation on hard clinical CVD endpoints of atherosclerosis. The absence of cardiovascular outcome trials using phytosterol or phytostanol supplementation makes it difficult to confirm a wider use in clinical practice, especially with the rapidly expanding list of effective and safe lipid-lowering medications.

The LDLc-lowering effect of phytosterols mediated by reduced intestinal cholesterol absorption has a possible consequence in the accumulation of plant sterols in atherosclerotic plaques, as shown in isolated tissues from patients undergoing carotid endarterectomy. An analysis of these specimens showed that the higher the ratio of the dietary sterol (cholestanol, campesterol, sitosterol, and avenasterol) to serum cholesterol, the higher a similar ratio in the carotid artery wall.

Evidence strength: The hard cardiovascular outcome data remain absent; evidence is limited to surrogate biomarker studies. This is an important gap in the clinical evidence base.

6.3 Cancer: Epidemiological and Preclinical Evidence

Epidemiological and experimental studies suggest that dietary phytosterols may offer protection from the most common cancers in Western societies, such as colon, breast, and prostate cancer. Possible mechanisms include the effect of phytosterols on membrane structure and function of tumor and host tissue, signal transduction pathways that regulate tumor growth and apoptosis, immune function of the host, and cholesterol metabolism by the host.

A systematic meta-analysis on phytosterols and cancer risk found that the summary relative risk for the highest versus the lowest campesterol intake was 0.72 (95% CI = 0.51–1.00). In a dose-response analysis, the results suggested a linear association for campesterol. The findings support the hypothesis that high phytosterol intake is inversely related to risk of cancer. However, the CI for campesterol alone just touches 1.00, making the finding marginally statistically significant, and the evidence remains epidemiological/observational rather than from controlled intervention trials.

In in vitro research on ovarian cancer, campesterol activates cell death signals and cell death in human ovarian cancer cells. Excessive calcium levels and ROS production were induced by campesterol in two selected ovarian cancer cell lines. Moreover, campesterol suppressed cell proliferation, cell cycle progression, and cell aggregation in ovarian cancer cells. Campesterol also enhanced the anticancer effects of conventional anticancer agents. These findings are preclinical and in vitro only.

Recent studies have shown that campesterol exhibits anticancer properties, particularly by inhibiting the metastasis of ovarian cancer, leukaemia, and hepatocellular carcinoma cells. Again, these findings are derived from cell-culture and/or animal studies.

Several possible anticancer mechanisms of phytosterols have been proposed, including inhibiting the production of carcinogens; inhibiting the proliferation, invasion, and metastasis of cancer cells; inducing apoptosis; and arresting the cell cycle.

Evidence strength: Anticancer evidence for campesterol specifically is preliminary and largely preclinical (in vitro and animal). Epidemiological data are supportive but not conclusive. No controlled human clinical trials have established campesterol as an anticancer intervention.

6.4 Prostate Health and 5-Alpha Reductase Inhibition

Steroidal 5α-reductase type 2 (S5αR2) is a key enzyme involved in the conversion of testosterone to dihydrotestosterone (DHT), a crucial process in the development of benign prostatic hyperplasia (BPH). Phytosterols, natural plant-derived compounds, have been proposed as potential inhibitors of S5αR2, but studies on their efficacy are limited. One study evaluated the inhibitory effects of three phytosterols (β-sitosterol, stigmasterol, and campesterol) on S5αR2 activity using a combined in vitro and in silico approach.

Evidence strength: Evidence for campesterol's role in prostate health and 5-alpha reductase inhibition is very preliminary, consisting of in vitro and computational (in silico) data only. No human clinical trials have tested campesterol alone for BPH.

6.5 Anti-Inflammatory Activity

Medicinal plants containing phytochemicals such as campesterol have been recognized as significant alternatives for the treatment of rheumatoid arthritis (RA). Campesterol exhibits the capacity to regulate interleukins and immune modulation in vitro and in vivo experimental models.

A study by Nazir et al. (2023) reported that campesterol exhibited a positive therapeutic effect on arthritic rats, showing its potential in treating inflammatory disorders. These are animal (rodent) data; no randomized human clinical trials have specifically tested campesterol's anti-inflammatory effect in arthritic patients.

Evidence strength: Anti-inflammatory activity is supported by in vitro and in vivo animal studies, and by a plausible mechanism involving NF-κB and cytokine pathways. Human clinical evidence is absent.

6.6 Campesterol as a Diagnostic/Research Biomarker

Beyond its pharmacological potential, serum campesterol has been extensively validated as a biomarker of intestinal cholesterol absorption efficiency in research settings. Beta-sitosterol and campesterol are the predominant phytosterols in blood. Compared to controls, cholesterol absorption in gallstone carriers was diminished by about 21% based on low serum sitosterol (P = 0.0269) and campesterol (P = 0.0231) to cholesterol ratios.

Empagliflozin (an SGLT2 inhibitor) increases serum campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes. This increase may be associated with SGLT2 inhibitor-induced increases in HDL cholesterol.

Cross-sectional studies have examined whether SNPs in genes encoding for proteins involved in intestinal cholesterol absorption (ABCG5, ABCG8, and NPC1L1) are associated with intestinal cholesterol absorption markers including TC-standardized campesterol and sitosterol levels. ABCG5 (rs4245786) and the tag SNP ABCG8 (rs4245791) were significantly associated with serum campesterol and/or sitosterol levels.

7. Body Systems and Health Areas of Association

• Cardiovascular system: Primary area of research; competitive inhibition of intestinal cholesterol absorption and consequent LDL lowering; uncertain effects on atherosclerosis risk and hard outcomes.
• Gastrointestinal system: Site of primary action — the small intestinal lumen, where campesterol displaces cholesterol from mixed micelles; modulation of NPC1L1 and ABCG5/ABCG8 transporter activity.
• Immune system / Inflammatory pathways: Preclinical evidence for modulation of NF-κB, TNF-α, IL-6, IL-1β, and COX-2 pathways.
• Oncology: Preclinical and epidemiological associations with reduced cancer risk; demonstrated in vitro activity against ovarian cancer, leukaemia, and hepatocellular carcinoma cell lines.
• Endocrine / Reproductive system: Preclinical evidence for inhibition of 5-alpha reductase (relevant to BPH); role as a biosynthetic precursor in steroidogenesis.
• Liver: Hepatic ABCG5/ABCG8 transporters regulate biliary secretion of campesterol; elevated campesterol in sitosterolemia has hepatic consequences.
• Central nervous system: Research confirms that a leaking blood-brain barrier causes increased flux of plant sterols, including campesterol, into the brain, raising questions about the role of campesterol accumulation in neurological conditions — an area of emerging but very preliminary investigation.

8. Dosage Forms and Reported Dosages

Campesterol is not typically administered as an isolated compound in clinical practice or supplement use; it is a constituent of combined phytosterol preparations. The dosages reported below refer to total phytosterol preparations containing campesterol as a significant component.

• Clinical studies consistently indicate that the intake of phytosterols at 2 g/day is associated with a significant reduction (8–10%) in LDL-cholesterol. Several guidelines recommend the intake of 2 g/day of plant sterols and/or stanols.
• The EFSA concluded that blood cholesterol can be reduced on average by 7 to 10.5% if a person consumes 1.5 to 2.4 grams of plant sterols and stanols per day, an effect usually established within 2–3 weeks.
• A meta-analysis of 124 RCTs found that the LDLc-lowering effect continues to increase up to intakes of approximately 3 g/day to an average effect of 12%, and doses higher than 3 g/day appear to be well tolerated.
• One randomized, double-blind, crossover study tested a phytosterol emulsion at 1.5 g/day phytosterol equivalents in 32 healthy adults over one month per study phase.
• Ingestion of plant sterols may decrease LDL-C concentrations by 12.1 mg/dL (0.32 mmol/L), an effect more evident with daily doses ≥ 2 g/day and in patients with LDL-C ≥ 140 mg/dL (3.68 mmol/L).
• As the typical Western diet contains only about 300 mg/day of phytosterols, foods enriched with phytosterols are usually used to achieve the recommended therapeutic intake.

It is difficult to incorporate free sterols into edible fats and/or oils because of their insolubility, whereas sterols esterified to fatty acids are more fat-soluble. In the intestine, most sterol esters are hydrolyzed to free sterols as part of the normal digestive process. This pharmacokinetic consideration underpins the development of sterol-ester formulations for functional foods.

9. Safety Considerations and Notable Interactions

General Safety Profile

Phytosterols have a long history of safe use, dating back to Cytellin marketed in the US from 1954 to 1982. Phytosterol esters have GRAS status in the US. Phytosterol-containing functional foods were subject to post-launch monitoring after being introduced to the EU market in 2000, and no unpredicted side effects were reported.

Sitosterolemia (Phytosterolemia): Pathological Accumulation

The most clinically serious safety concern involves individuals with the rare inherited disorder sitosterolemia (phytosterolemia). Sitosterolemia is a rare autosomal recessive disorder of lipid metabolism characterized by markedly elevated plant sterol concentrations in blood (e.g., sitosterol, campesterol, and stigmasterol) due to increased intestinal absorption and decreased biliary secretion. In this disorder, an excess of many plant sterols is absorbed and not enough excreted. Patients can develop atherosclerosis and coronary heart disease as early as childhood, as well as other problems including arthritis, arthralgia, and tendon xanthomas (lipid deposits).

Concern principally originates from evidence that accumulated plant sterols have toxic effects, and that patients with sitosterolemia, and animals with mutant or absent ABCG5 and ABCG8 transporter genes — which have increased absorption, decreased secretion, and higher plasma neutral sterol levels — exhibit signs of premature atherosclerosis; i.e., plant sterols may be proatherogenic when in excess.

A potential safety concern regarding phytosterol consumption is in patients with phytosterolaemia, a rare genetic disorder which results in a 50- to 100-fold increase in blood plant sterol levels and is associated with rapid development of coronary atherosclerosis.

Cardiovascular Uncertainty at Supplemented Doses

Excessive use of plant sterols has been associated with an increased risk of cardiovascular disease, and genetic conditions that cause extremely elevated levels of some phytosterols, such as sitosterol, are associated with higher risks of cardiovascular disease. Although plant sterols, once absorbed, can promote atherosclerosis, their intake is believed to be safe because of poor absorption, except in rare hyperabsorbers with homozygous ABCG5/8 mutations.

Fat-Soluble Vitamin and Carotenoid Interactions

Phytosterol-enriched preparations may reduce the absorption of some fat-soluble vitamins. This interaction is a recognized and documented concern: clinical and meta-analytic data indicate that regular consumption of phytosterol-enriched foods can reduce circulating levels of fat-soluble vitamins and carotenoids such as beta-carotene, lycopene, and vitamin E, likely through the same micellar displacement mechanism that reduces cholesterol absorption. This is particularly relevant when intake exceeds the 2–3 g/day range and when dietary intake of carotenoid-rich vegetables is low.

Drug Interactions

Medications such as ezetimibe may effectively reduce cholesterol and phytosterol absorption. Because campesterol serves as a validated biomarker of cholesterol absorption, drugs that affect NPC1L1-mediated intestinal sterol uptake — most prominently ezetimibe — will directly reduce circulating campesterol levels. In a reported case, markedly high serum campesterol levels (66.0 μg/mL) were largely reduced by insulin treatment; the addition of ezetimibe normalized plant sterol levels. Statins, which increase cholesterol synthesis and upregulate LDL receptor expression, may also indirectly affect campesterol levels by altering the lathosterol-to-campesterol ratio used clinically to monitor statin response versus phytosterol response.

Diabetes and Altered Absorption States

Evidence exists that uncontrolled diabetes plays a causal role in the pathogenesis of phytosterolemia. In patients with poorly controlled diabetes, plant sterol absorption — including that of campesterol — may be elevated even in individuals who are heterozygous carriers of ABCG5 mutations, representing an interaction between metabolic disease state and phytosterol handling that warrants clinical awareness.

Pregnancy and Specific Populations

Campesterol has been identified in human milk fat globule membranes, where it originates exclusively from the mother's diet. The clinical implications of this dietary-to-milk transfer for breastfed infants have not been fully characterized, and current guidelines generally advise against phytosterol-enriched product use in pregnant and breastfeeding women pending further evidence.

Blood-Brain Barrier Permeability

Research confirms that a leaking blood-brain barrier causes increased flux of plant sterols, including campesterol, into the brain. The significant flux of labeled plant sterols into the brain of control mice illustrates that the presence of an alkyl group in the 24-position of the steroid side chain markedly increases the ability of cholesterol to pass an intact BBB. There is discussion of the possibility that a specific transport mechanism is involved in the flux of alkylated cholesterol species across the BBB. The clinical relevance of this BBB-crossing property of campesterol in the context of neurological disease or drug-nutrient interactions remains an open research question.

10. Regulatory Status

Phytosterol esters have generally recognized as safe (GRAS) status in the US. In the European Union, campesterol and other phytosterols are regulated as novel food ingredients when used at supplementary levels above what would be obtained from conventional foods. In EU countries, products enriched in plant sterols are mainly milk and yogurt, margarine, and spreadable fats, all regulated under the Novel Foods Regulation framework. The EFSA scientific panel has provided the following health advisory: "Plant sterols have been shown to lower/reduce blood cholesterol," with an authorized health claim in the EU specifically linking 1.5–3 g/day of plant sterols to reductions in blood cholesterol.

References

• Wikipedia: Campesterol
• ScienceDirect Topics: Campesterol (Nursing and Health Professions overview)
• ScienceDirect Topics: Campesterol (Chemistry overview)
• Poli A, et al. Phytosterols in the Treatment of Hypercholesterolemia and Prevention of Cardiovascular Diseases. E&M, 2017. PMC5729784
• Pirro M, et al. Plant Sterols and Plant Stanols in Cholesterol Management and Cardiovascular Prevention. PMC10343346
• Demonty I, et al. Plant sterols/stanols as cholesterol lowering agents: A meta-analysis of randomized controlled trials. PMC2596710
• A Randomized, Placebo-Controlled, Double-Blind Crossover Study to Assess a Unique Phytosterol Ester Formulation in Lowering LDL Cholesterol. PMC6769481
• Schwarz JM, et al. Plasma Biomarker of Dietary Phytosterol Intake. PMC4323197
• Paneni F, et al. Could Lowering Phytosterol Absorption as Part of Lipid-Lowering Therapy Have a Beneficial Effect on Residual Risk? PMC9964413
• Bae SY, et al. Disruption of Endoplasmic Reticulum and ROS Production in Human Ovarian Cancer by Campesterol. PMC8001332
• Jiang L, et al. The Protective Effect of Dietary Phytosterols on Cancer Risk: A Systematic Meta-Analysis. PMC6612402
• Phytosterols: Physiological Functions and Potential Application. PMC11171835
• Björkhem I, et al. Increased flux of plant sterols campesterol and sitosterol across a disrupted blood brain barrier. PubMed 25683892
• Lütjohann D, et al. Ratio of lathosterol to campesterol in serum predicts the cholesterol-lowering effect of sitostanol-supplemented margarine. PubMed 16035372
• Jojima T, et al. Empagliflozin increases plasma levels of campesterol in patients with type 2 diabetes. PubMed 33556413
• Genome-wide association study and meta-analysis of phytosterols identifies a novel locus for serum levels of campesterol. Human Genomics, 2024.
• Adam MP, et al. Sitosterolemia. GeneReviews®, NCBI Bookshelf. NIH.
• A Cytotoxic and Anti-inflammatory Campesterol Derivative from Genetically Transformed Hairy Roots of Lopezia racemosa. PMC6155711
• Plant sterol hyperabsorption caused by uncontrolled diabetes in a patient with a heterozygous ABCG5 variant. PMC9623525
• Wang HH, et al. Relative roles of ABCG5/ABCG8 in liver and intestine. PMC4306686
• Associations between SNPs in Intestinal Cholesterol Absorption and Endogenous Cholesterol Synthesis Genes with Cholesterol Metabolism. PMC8533139
• Isolation, characterization, and docking studies of campesterol and β-sitosterol from Strychnos innocua. PMC9906018
• Buț MG, et al. Exploring the Inhibitory Potential of Phytosterols β-Sitosterol, Stigmasterol, and Campesterol on 5-Alpha Reductase Activity in the Human Prostate. PMC11597715
• Woyengo TA, et al. Anticancer effects of phytosterols. European Journal of Clinical Nutrition, 2009.
• Bradford PG, Awad AB. Phytosterols as Anticancer Dietary Components: Evidence and Mechanism of Action. Journal of Nutrition, 2000.
• Wikipedia: Phytosterol
• ClinicalTrials.gov: Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia. NHLBI/NIH.
• Phytosterols and phytostanols in context: From physiology and pathophysiology to food supplementation and clinical practice. Pharmacological Research, 2025.
• Unveiling the approach of campesterol: Its application and circular bio-economy. CABI Reviews, 2025.
• Klett EL, et al. Localization of ABCG5 and ABCG8 proteins in human liver, gall bladder and intestine. PMC522813